ESMO 2025

News

Boehringer Ingelheim and Bayer logos with lung sketch in the middle

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

News

ESMO: Grail's data on cancer blood test firms up

Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.

News

ESMO: Lilly reveals scale of survival win with Verzenio

Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.

Oncology

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

Oncology

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

ESMO: Grail's data on cancer blood test firms up

ESMO: Lilly reveals scale of survival win with Verzenio

ESMO 2025 commences: ADCs, AI, and Asia

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

ESMO 2025

Editor's Picks